Traws Pharma
TRAW
24 hedge funds and large institutions have $1.88M invested in Traws Pharma in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 5 closing their positions.
37% more capital invested
Capital invested by funds: $1.37M → $1.88M (+$513K)
0.01% more ownership
Funds ownership: 0.35% → 0.35% (+0.01%)
8% less funds holding
Funds holding: 26 → 24 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$53.5K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$28.4K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$771 |
| 4 |
OPTFSNA
Old Point Trust & Financial Services N A
Newport News,
Virginia
|
+$135 |
| 5 |
JP Morgan Chase
New York
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$14.5K |
| 2 |
HWA
Hillcrest Wealth Advisors
Hazlet,
New Jersey
|
-$12.5K |
| 3 |
Millennium Management
New York
|
-$11.5K |
| 4 |
BPA
Beacon Pointe Advisors
Newport Beach,
California
|
-$11.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$5.69K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HWA
26
Hillcrest Wealth Advisors
Hazlet,
New Jersey
| – | -$12.5K | -669 | Closed |
|
|
27
Millennium Management
New York
| – | -$11.5K | -620 | Closed |
|
28
Bank of America
Charlotte,
North Carolina
| – | -$506 | -27 | Closed |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$212 | -11 | -69% |
|
|
TWC
30
TD Waterhouse Canada
Toronto,
Ontario, Canada
| – | -$87 | -5 | Closed |
|
TRAW Hedge Fund Activity: Q1 2024 in Review
24 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2024, worth a combined $1.88M — up 37% from $1.37M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of TRAW and 3 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $53.5K. The largest seller was Morgan Stanley, cutting an estimated $14.5K.
- 24 institutional investors held Traws Pharma (TRAW) as of Q1 2024, down from 26 in Q4 2023.
- Funds reported $1.88M of Traws Pharma stock for Q1 2024, up 37% quarter-over-quarter.
- 3 funds opened new Traws Pharma positions in Q1 2024 and 5 closed out, a net change of -2 holders.
- The largest Traws Pharma buyer in Q1 2024 was Renaissance Technologies, an estimated $53.5K added.
- The largest Traws Pharma seller in Q1 2024 was Morgan Stanley, an estimated $14.5K sold.
Based on aggregated 13F filings for Q1 2024.